|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2001
|
|
gptkbp:ATCCode
|
gptkb:J05AB14
|
|
gptkbp:CASNumber
|
gptkb:175865-59-5
|
|
gptkbp:chemicalFormula
|
C14H22N6O5
|
|
gptkbp:contraindication
|
hypersensitivity to ganciclovir
hypersensitivity to valganciclovir
|
|
gptkbp:drugClass
|
antiviral drug
antiviral
|
|
gptkbp:form
|
gptkb:tablet
oral solution
|
|
gptkbp:genericName
|
gptkb:valganciclovir
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Valcyte
|
|
gptkbp:indication
|
treatment of CMV retinitis in AIDS patients
prevention of CMV disease in kidney, heart, and kidney-pancreas transplant recipients
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Roche
|
|
gptkbp:mechanismOfAction
|
inhibits viral DNA synthesis
|
|
gptkbp:metabolism
|
gptkb:ganciclovir
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:pregnancyRisk
|
may cause birth defects
|
|
gptkbp:prescriptionStatus
|
Rx-only
|
|
gptkbp:prodrugOf
|
gptkb:ganciclovir
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
fever
nausea
vomiting
diarrhea
neutropenia
thrombocytopenia
|
|
gptkbp:usedFor
|
gptkb:cytomegalovirus_infection
prevention of CMV disease in transplant patients
|
|
gptkbp:bfsParent
|
gptkb:valganciclovir
gptkb:F._Hoffmann-La_Roche_AG
|
|
gptkbp:bfsLayer
|
7
|